132 related articles for article (PubMed ID: 37951220)
1. Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study.
Little RD; Swaine A; Reynolds R; Gibson DJ; Barrau M; D'Errico F; Hampal R; Sparrow MP; Roblin X; Irving PM; Ward MG
Inflamm Bowel Dis; 2023 Nov; ():. PubMed ID: 37951220
[TBL] [Abstract][Full Text] [Related]
2. Treatment With Adalimumab 80 mg Every Other Week in Inflammatory Bowel Disease: Results of Treatment Intensification in Clinical Practice.
Calvo Moya M; González Lama Y; Ruíz Antorán B; Omella Usieto I; El Hajra Martinez I; Santos Pérez E; Menchén Viso B; Matallana Royo V; González Partida I; de Lucas Tellez de Meneses R; Bella Castillo P; González Rodriguez M; Vera Mendoza MI
Crohns Colitis 360; 2023 Jan; 5(1):otac051. PubMed ID: 36785555
[TBL] [Abstract][Full Text] [Related]
3. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
[TBL] [Abstract][Full Text] [Related]
4. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.
Billioud V; Sandborn WJ; Peyrin-Biroulet L
Am J Gastroenterol; 2011 Apr; 106(4):674-84. PubMed ID: 21407178
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease.
Stallhofer J; Guse J; Kesselmeier M; Grunert PC; Lange K; Stalmann R; Eckardt V; Stallmach A
Int J Colorectal Dis; 2023 Feb; 38(1):54. PubMed ID: 36840779
[TBL] [Abstract][Full Text] [Related]
6. Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn's Perianal Fistulae.
Maas L; Gao R; Cusumano V; Spartz E; Chowdhury R; Krishna M; Lazarev M; Melia J; Selaru F; Sharma S; Limketkai B; Parian A
Dig Dis Sci; 2023 Oct; 68(10):3994-4000. PubMed ID: 37540392
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab.
Mizoshita T; Tanida S; Ozeki K; Katano T; Shimura T; Mori Y; Kubota E; Kataoka H; Kamiya T; Joh T
Case Rep Gastroenterol; 2016; 10(2):283-91. PubMed ID: 27462198
[TBL] [Abstract][Full Text] [Related]
8. Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission.
Plevris N; Lyons M; Jenkinson PW; Chuah CS; Merchant LM; Pattenden RJ; Watson EF; Ho GT; Noble CL; Shand AG; Din S; Arnott ID; Jones GR; Lees CW
Inflamm Bowel Dis; 2019 May; 25(6):1036-1043. PubMed ID: 30335139
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Drug Monitoring Guides the Management of Crohn's Patients with Secondary Loss of Response to Adalimumab.
Restellini S; Chao CY; Lakatos PL; Aruljothy A; Aziz H; Kherad O; Bitton A; Wild G; Afif W; Bessissow T
Inflamm Bowel Dis; 2018 Jun; 24(7):1531-1538. PubMed ID: 29668893
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a novel therapeutic drug monitoring-based nomogram for prediction of primary endoscopic response to anti-TNF therapy in active Crohn's disease.
Chen L; Kang D; Fang L; Sun M; Li M; Zhou G; Xu C; Pang Z; Ye Y; Feng B; Wu H; Lin J; Ding B; Liu C; Shi Y; Liu Z
Therap Adv Gastroenterol; 2024; 17():17562848241256237. PubMed ID: 38827646
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease.
Orts B; Gutierrez A; Madero L; Sempere L; Frances R; Zapater P
Front Pharmacol; 2021; 12():795272. PubMed ID: 35046819
[No Abstract] [Full Text] [Related]
12. Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn's Disease: A Hospital-Based Cohort Study from Korea.
Seo H; Ye BD; Song EM; Lee SH; Chang K; Lee HS; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK
Dig Dis Sci; 2017 Oct; 62(10):2882-2893. PubMed ID: 28822006
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
[TBL] [Abstract][Full Text] [Related]
14. No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification.
Paul S; Williet N; Nancey S; Veyrard P; Boschetti G; Phelip JM; Flourie B; Roblin X
Dig Dis Sci; 2021 Aug; 66(8):2744-2749. PubMed ID: 32936345
[TBL] [Abstract][Full Text] [Related]
15. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
Assa A; Matar M; Turner D; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Shamir R
Gastroenterology; 2019 Oct; 157(4):985-996.e2. PubMed ID: 31194979
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E
Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
Imaeda H; Takahashi K; Fujimoto T; Bamba S; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
J Gastroenterol; 2014 Jan; 49(1):100-9. PubMed ID: 23575576
[TBL] [Abstract][Full Text] [Related]
18. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
Roblin X; Rinaudo M; Del Tedesco E; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Am J Gastroenterol; 2014 Aug; 109(8):1250-6. PubMed ID: 24913041
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
Inokuchi T; Takahashi S; Hiraoka S; Toyokawa T; Takagi S; Takemoto K; Miyaike J; Fujimoto T; Higashi R; Morito Y; Nawa T; Suzuki S; Nishimura M; Inoue M; Kato J; Okada H
J Gastroenterol Hepatol; 2019 Aug; 34(8):1329-1336. PubMed ID: 30724387
[TBL] [Abstract][Full Text] [Related]
20. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
